How most favored nation policy is reshaping pharmaceutical pricing and market access

In July 2025, MFN policy moved from conceptual pilot to active enforcement, with formal compliance letters issued to pharmaceutical manufacturers and subsequent implementation steps reshaping pricing and access considerations into 2026.

MFN pricing links U.S. drug prices to international benchmarks, fundamentally changing how global pricing, launch planning, and market access decisions must be approached. While the policy has been discussed for several years, recent enforcement activity has elevated MFN from theoretical risk to an operational pricing reality.

For pharmaceutical leaders, the core challenge is not understanding the existence of MFN, but understanding where and how exposure materializes across assets and markets, and how pricing, access, and value decisions must now be made under tighter global constraints.

This white paper examines how most‑favored nation policy affects pharmaceutical pricing and market access decisions across assets, markets, and launch strategies.

What changed after enforcement began in July 2025?

In July 2025, federal agencies issued compliance letters to a group of pharmaceutical manufacturers requiring action within defined timelines, signaling a shift from policy intent to enforceable expectations. These actions were followed by additional steps later in 2025, including voluntary manufacturer agreements, expanded expectations for new product launches, and the introduction of structured CMS payment models affecting Medicare and Medicaid programs.

Pricing and market access implications

MFN introduces sustained downward pressure on U.S. list prices by tying them directly to prices in select high‑income countries. Because launch prices are now subject to immediate international benchmarking, decisions made in ex‑U.S. markets can carry direct consequences for U.S. pricing and access outcomes.

This dynamic alters traditional pricing corridors, heightens payer scrutiny, and places increased importance on cross‑market price consistency. For many products, especially high‑cost specialty therapies, these effects extend beyond pricing into access timing, reimbursement conditions, and real‑world uptake.

The role of evidence, value, and scenario planning

As pricing flexibility compresses, evidence and value positioning play a more central role in sustaining access across markets. Robust economic models and outcomes data are increasingly required to support pricing rationale under MFN constraints.

Scenario‑based planning is critical in this environment. The white paper examines how different launch sequencing and pricing strategies produce materially different long‑term outcomes, demonstrating that when and where products launch can influence global value capture under MFN pricing frameworks.

Download this policy brief to understand how the most‑favored nation policy is reshaping pharmaceutical pricing and access strategy, and how recent developments translate into real‑world decision considerations. Reframe what’s possible in pricing and access decision‑making.

Start the Assessment →  MFN Exposure Assessment

Download the Policy Brief Now